zoledronic acid has been researched along with Adverse Drug Event in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Curraj, E; Gonzalez Rodriguez, E | 1 |
| Bradbury, BD; Brookhart, MA; Curtis, JR; Ehrenstein, V; Levintow, SN; McGrath, LJ; Reams, D; Saul, B; Spangler, L; Sørensen, HT | 1 |
| Cruz, C; Miyashita, H; Smith, C | 1 |
| Arnaud, L; Javier, RM; Lebrun-Vignes, B; Pijnenburg, L; Salem, JE; Sibilia, J | 1 |
| Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW | 1 |
| Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN | 1 |
| Chen, F; Pu, F | 1 |
| Black, DM; Boonen, S; Colón-Emeric, CS; Eastell, R; Eriksen, EF; Haentjens, P; Lyles, KW; Magaziner, JS; Mesenbrink, P | 1 |
| Eidtmann, H; Gnant, M | 1 |
| Black, DM; Gamble, GD; Lakatos, P; Mesenbrink, P; Reid, IR | 1 |
| Aapro, M; Coleman, R; Gnant, M; Hadji, P; Lipton, A | 1 |
| Brown, J; Burkinshaw, R; Coleman, R; Lester, J; Neville-Webbe, H; Winter, M; Woodward, E | 1 |
| Giraldo-Giraldo, C; Machado-Alba, JE; Moncada-Escobar, JC | 1 |
| Bell, R; Bourgeois, H; Braun, A; Brufsky, A; Chung, K; Dansey, R; Diel, I; Eniu, A; Fallowfield, L; Fan, M; Fujiwara, Y; Jassem, J; Jiang, Q; Martin, M; Paterson, AH; Ritchie, D; Steger, GG; Stopeck, A; Vogel, C | 1 |
| Hussar, DA | 1 |
| Beamer, E; Kriegman, A; Lindsay, R; Saag, K; Zhou, W | 1 |
| Fantini, M; Nicoletti, S; Poggi, B; Possenti, C; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Avanzati, A; De Paola, V; Gennari, L; Martini, G; Merlotti, D; Nuti, R; Valleggi, F | 1 |
5 review(s) available for zoledronic acid and Adverse Drug Event
| Article | Year |
|---|---|
Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Atrial Fibrillation; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Male; North America; Pamidronate; Pharmacoepidemiology; Pharmacovigilance; World Health Organization; Zoledronic Acid | 2021 |
Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Causality; Comorbidity; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Imidazoles; Male; Patient Safety; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Zoledronic Acid | 2016 |
The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ...
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Zoledronic Acid | 2010 |
Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Injections, Intravenous; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
Zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Fractures, Bone; Humans; Imidazoles; Zoledronic Acid | 2011 |
5 trial(s) available for zoledronic acid and Adverse Drug Event
| Article | Year |
|---|---|
Characterization of and risk factors for the acute-phase response after zoledronic acid.
Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Incidence; Osteoporosis, Postmenopausal; Risk Factors; Severity of Illness Index; Time Factors; Zoledronic Acid | 2010 |
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Quality of Life; RANK Ligand; Zoledronic Acid | 2012 |
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Peptides; Postmenopause; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2007 |
Zoledronic acid treatment at home: safety data from an observational prospective trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Home Care Services; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Multiple Myeloma; Observation; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Time Factors; Zoledronic Acid | 2007 |
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Topics: Aged; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Osteitis Deformans; Pain; Pamidronate; Quality of Life; Time Factors; Zoledronic Acid | 2007 |
10 other study(ies) available for zoledronic acid and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Side effects of osteoporosis treatments: how to explain them to patients?]
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid | 2023 |
Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Confounding Factors, Epidemiologic; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Middle Aged; Osteoporosis, Postmenopausal; Sensitivity and Specificity; United States; Zoledronic Acid | 2020 |
Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Musculoskeletal Abnormalities; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2021 |
Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center.
Topics: Adult; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Zoledronic Acid | 2022 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Immunohistochemistry; Integrins; Jaw; Microscopy, Electron, Scanning; Mouth Mucosa; Osteonecrosis; Pamidronate; Sarcoglycans; Zoledronic Acid | 2013 |
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Topics: Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Femoral Neck Fractures; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Medication Adherence; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2010 |
[Active pharmacosurveillance of patients affiliated to the Colombian general social security/health system].
Topics: Adverse Drug Reaction Reporting Systems; Calcium Channel Blockers; Clopidogrel; Colombia; Diphosphonates; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Losartan; Medication Systems; Metoprolol; National Health Programs; Omeprazole; Retrospective Studies; Social Security; Software; Ticlopidine; Zoledronic Acid | 2010 |
New drugs 2002, part III.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid | 2002 |